Pfizer Discontinues Mesothelin-Targeting ADC PF-08052666 Amid Strategic Pipeline Restructuring
核心洞察
Pfizer has discontinued development of PF-08052666, an anti-mesothelin antibody-drug conjugate, citing "business strategic reasons" rather than safety concerns.
The decision follows a pattern of mesothelin-targeting therapy failures, including Zymeworks' T-cell engager ZW171, highlighting ongoing challenges with this target.
PF-08052666's discontinuation leaves RemeGen's RC88 as the only clinical-stage mesothelin-targeting ADC currently in development.
Pfizer has discontinued development of PF-08052666, an anti-mesothelin antibody-drug conjugate (ADC), marking another setback for therapies targeting this challenging oncology target. The pharmaceutical giant confirmed the decision was made for "business strategic reasons" and was not driven by safety concerns, regulatory requests, or conduct issues.
The discontinuation became apparent when the recruitment target for PF-08052666's phase 1 solid tumor (搜索) trial was dramatically reduced from 365 to just 19 patients, and the study status changed from "recruiting" to "active, not recruiting" on clinicaltrials.gov.
Mesothelin Target Faces Continued Challenges
The decision appears to reflect broader difficulties with mesothelin as a therapeutic target rather than issues with the underlying ADC technology. Mesothelin has experienced a series of clinical failures, with the most recent being Zymeworks' T-cell engager ZW171. This pattern of setbacks has raised questions about the viability of mesothelin-directed therapies across different modalities.
PF-08052666's removal from Pfizer's pipeline leaves RemeGen's RC88 as the only clinical-stage mesothelin-targeting ADC currently in development, according to OncologyPipeline data. However, several preclinical candidates remain in development, suggesting continued industry interest despite the clinical challenges.
Tmalin Technology Platform Remains Active
The discontinued asset, also known as HBM9033, was originally developed by MediLink (搜索) and Harbour BioMed (搜索) using MediLink's Tmalin linker-payload technology. Pfizer licensed global rights to the compound in December 2023 for $53 million upfront. Despite this setback, the Tmalin platform continues to attract pharmaceutical partnerships, with Roche recently acquiring MediLink's lead anti-B7-H3 ADC tambotatug pelitecan (搜索) in a deal potentially worth up to $570 million.
The Tmalin technology, described as a tumor microenvironment "activable" linker-payload system, has been adopted by multiple companies including Astellas, Zai Lab, and BioNTech for their respective ADC programs.
Broader Pipeline Restructuring
The PF-08052666 discontinuation is part of a broader pipeline restructuring at Pfizer, which has made several recent oncology program discontinuations. The company has also discontinued development of a pan-KRAS inhibitor PF-07985045 and a PD-L1-targeting conjugate PF-08046037, among other assets.
The next potential mesothelin readout in the clinical landscape could come from Context (搜索)'s T-cell engager CT-95, which is expected to yield phase 1 data in mid-2026. This timeline will provide additional insights into whether alternative approaches to targeting mesothelin can overcome the challenges that have plagued previous attempts.